Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or

in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 28 MAY, 2013

Reference is made to the notice (the "Notice") of extraordinary general meeting (the "EGM") and the circular of Sino Biopharmaceutical Limited (the "Company") dated 24 April, 2013 setting out information relating to, inter alia, the New Share Option Scheme (the "Circular"). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.
The Board is pleased to announce that the resolution proposed at the EGM was duly passed by the
Shareholders by way of poll as an ordinary resolution at the EGM held on Tuesday, 28 May, 2013.

POLL RESULTS OF THE EGM

As at the date of the EGM, the total number of issued Shares was 4,941,461,473 Shares, being the total number of Shares entitling the Shareholders to attend and vote for and against the resolution proposed at the EGM. No Shareholder has a material interest in the adoption of the New Share Option Scheme, and hence no Shareholder was required to abstain from voting on relevant resolution at the EGM. There was no Shareholder who was entitled to attend the EGM but was only entitled to vote against the resolution.
The Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, was appointed as the scrutineer of the vote-taking at the EGM.

1

The poll results in respect of the resolution proposed at the EGM are as follows:

Number of votes

(approximate %)

Ordinary resolution

For

Against

To pass the ordinary resolution regarding the adoption of the

new share option scheme of the Company set out in the Notice of Extraordinary General Meeting.

3,621,613,073

(96.49%)

131,704,699

(3.51%)

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the EGM in person, by corporate representative or by proxy.

As more than 50% of the votes were cast in favour of the resolution, the resolution set out above was duly passed as an ordinary resolution of the Company.
By Order of the Board

Sino Biopharmaceutical Limited Tse Ping

Chairman

Hong Kong, 28 May, 2013

As at the date of this announcement, the Board of Directors of the Company comprises seven executive directors, namely Mr. Tse Ping, Mr. Zhang Baowen, Mr. Xu Xiaoyang, Mr. Tse Hsin, Ms. Cheng Cheung Ling, Mr. Tao Huiqi and Mr. He Huiyu and four independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Li Jun and Mr. Mei Xingbao.

2

distributed by